UAE Recombinant Protein Therapeutics Cdmo Market Size & Outlook
UAE recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
UAE recombinant protein therapeutics cdmo market highlights
- The UAE recombinant protein therapeutics cdmo market generated a revenue of USD 134.2 million in 2023 and is expected to reach USD 312.8 million by 2030.
- The UAE market is expected to grow at a CAGR of 12.9% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 134.2 million |
| Market revenue in 2030 | USD 312.8 million |
| Growth rate | 12.9% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, UAE accounted for 0.6% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 312.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.46% in 2023. Horizon Databook has segmented the UAE recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
The UAE government is continuously involved in activities to support healthcare development in the region. The renewal of drug development policies, entry of new players, and investment of foreign pharmaceutical companies & CDMOs offer lucrative growth opportunities to the recombinant protein therapeutics CDMO services market.
In addition, the government’s spending on healthcare infrastructure and supportive government policies for foreign manufacturers are anticipated to boost the market over the forecast period. Moreover, the market is fueled by domestic players who expand their geographical presence through various strategies.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UAE recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
UAE Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
